[{"id":11,"text":"In patients with non-small cell lung cancer harboring EML4-ALK fusion, the L1196M variant has been shown to confer resistance to crizotinib.","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Choi et al., 2010, N. Engl. J. Med.","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/20979473","pubmed_id":"20979473","drugs":[{"id":6,"name":"Crizotinib","pubchem_id":null}],"rating":4,"evidence_level":"B","evidence_type":"Predictive","clinical_significance":"Resistance or Non-Response","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"},{"id":10,"text":"CH5424802 treatment resulted in significant tumor regression in xenograft models produced from Ba/F3 cells expressing EML4-ALK or AML4-ALK with the L1196M mutation","disease":"Non-small Cell Lung Carcinoma","doid":"3908","citation":"Sakamoto et al., 2011, Cancer Cell","source_url":"http://www.ncbi.nlm.nih.gov/pubmed/21575866","pubmed_id":"21575866","drugs":[{"id":7,"name":"CH5424802","pubchem_id":null}],"rating":3,"evidence_level":"C","evidence_type":"Predictive","clinical_significance":"Sensitivity","evidence_direction":"Supports","variant_hgvs":"N/A","variant_origin":"Somatic"}]